Atagabalin, formerly known as PD 0200390, is a gabamimetic agent under development for the treatment for insomnia. Atagabalin is related to gabapentin, which similarly binds to the α2δ calcium channels (1 and 2). It was discontinued following unsatisfactory trial results. References: Kjellsson MC, Ouellet D, Corrigan B, Karlsson MO. Modeling sleep data for a new drug in development using markov mixed-effects models. Pharm Res. 2011 Oct;28(10):2610-27. doi: 10.1007/s11095-011-0490-x. Epub 2011 Jun 17. PubMed PMID: 21681607.

纯度：≥98%

CAS：223445-75-8